Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis
The Laryngoscope · 29.08.2024
DOI: 10.1002/lary.31706 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Laryngoscope, online erschienen am 29.08.2024. Verfasst von Yufei Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Bevacizumab, Respiratory Tract Infections, Papillomavirus Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Programs of the Natural Science Foundation of Jiangsu, Nanjing Medical Science and Technology Development Fund, Foundation of Nanjing Medical University.
Abstract (Originalsprache)
Objectives
To develop and validate a novel method for quantifying the efficacy of Bevacizumab (Bev) in treating Recurrent Respiratory Papillomatosis (RRP), and to evaluate the clinical outcomes of a three‐dose Bev induction therapy followed by surgical intervention.
Methods
Twenty‐one RRP patients treated with a three‐dose Bev regimen were included. A novel efficacy evaluation method using ImageJ software was developed to calculate the standardized lesion volume from laryngoscopic images. This was compared with the Derkay score. Clinical outcomes, including reduction rate, cumulative reduction rate, efficacy grading, recurrence, and adverse reactions, were analyzed.
Results
In the study cohort, the reduction rate was significantly higher after the first treatment compared with subsequent treatments. The overall response rate increased from 75% after the first treatment to 100% after the third. Among patients with localized lesions who underwent surgery, 76% experienced recurrence with a mean recurrence time of 114.23 days. Most recurrent lesions were smaller than at baseline. Adverse reactions included increased blood pressure in seven patients, which resolved without intervention. The new method showed a significant positive correlation with the Derkay score.
Conclusion
In conclusion, based on the above findings, systemic Bev treatment for RRP is a safe and effective therapeutic approach, though further research is needed. Moreover, the new efficacy evaluation method we developed can significantly aid in studying the effectiveness of Bev treatment for RRP. Level of Evidence 2 Laryngoscope , 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Southeast University, Nanjing, China.
- Department of Otolaryngology-Head and Neck Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China.
- Nanjing Medical Key Laboratory of Laryngopharynx-Head & Neck Oncology, Nanjing, China.
ORCID-Profile: Yufei Pan, Huili Huang, Chao Wang, Huiying Hu, Kai Sun, Kai Liu
Förderung
- Programs of the Natural Science Foundation of Jiangsu
- Nanjing Medical Science and Technology Development Fund
- Foundation of Nanjing Medical University
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Pan, Y., Lu, Y., Huang, H., Wang, C., Han, X., Hu, H., Sun, K., Li, J., Zhang, Y., Liu, K., & Yu, Z. (2024). Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis. The Laryngoscope. https://doi.org/10.1002/lary.31706
Vancouver
Pan Y, Lu Y, Huang H, Wang C, Han X, Hu H, et al. Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis. The Laryngoscope. 2024. doi:10.1002/lary.31706
BibTeX
@article{Pan2024,
author = {Pan, Yufei and Lu, Yuanyuan and Huang, Huili and Wang, Chao and Han, Xiao and Hu, Huiying and Sun, Kai and Li, Jing and Zhang, Yonghui and Liu, Kai and Yu, Zhenkun},
title = {Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31706}
}
EUVIMED